DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients

Phase 4

Completed

Conditions: Renal Function

Interventions: Drug: cyclosporine A
Drug: everolimus
Drug: Enteric Coated Mycophenolate Sodium (EC-MPS)
Drug: corticosteroids
Drug: Basiliximab

First Posted Date: 2008-03-13

Last Posted Date: 2014-08-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 204

Registration Number: NCT00634920

Locations: 🇸🇪
Novartis Investigative Site, Uppsala, Sweden

Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor

Phase 2

Completed

Conditions: Gastrointestinal Stromal Tumors (GIST)

Interventions: Drug: AMN107- NILOTINIB

First Posted Date: 2008-03-12

Last Posted Date: 2017-06-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 9

Registration Number: NCT00633295

Locations: 🇮🇱
Novartis Investigative Site, Tel Hashomer, Israel

Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis

Phase 2

Completed

Conditions: Chronic Anemia
Transfusional Hemosiderosis

Interventions: Drug: Deferasirox (ICL670)

First Posted Date: 2008-03-07

Last Posted Date: 2021-06-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 102

Registration Number: NCT00631163

Locations: 🇹🇷
Novartis Investigative Site, Izmir, Turkey

Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants

Phase 4

Completed

Conditions: Multiple Myeloma

Interventions: Drug: zoledronic acid

First Posted Date: 2008-02-25

Last Posted Date: 2021-05-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 121

Registration Number: NCT00622505

Locations: 🇺🇸
Loyola University Medical Center /Cardinal Bernardin Cancer Loyola Univ Med Ctr, Maywood, Illinois, United States
🇺🇸
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
Dana Farber Cancer Institute Clinical Research Coordinator, Boston, Massachusetts, United States

and more 39 locations

Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients

Phase 3

Completed

Conditions: Liver Transplantation

Interventions: Drug: Tacrolimus (reduced tacrolimus)
Drug: Tacrolimus (tacrolimus elimination)
Drug: Tacrolimus (tacrolimus control)
Drug: Everolimus (reduced tacrolimus)
Drug: Everolimus (tacrolimus elimination)
Drug: Corticosteroids

First Posted Date: 2008-02-25

Last Posted Date: 2013-05-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 719

Registration Number: NCT00622869

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Indacaterol 300 μg
Drug: Placebo to indacaterol
Drug: Salmeterol 50 μg

First Posted Date: 2008-02-25

Last Posted Date: 2011-08-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 68

Registration Number: NCT00622635

Locations: 🇪🇸
Novartis Investigator site, Mataro, Spain
🇪🇸
Novartis Investigator Site, Madrid, Spain

A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies

Phase 1

Completed

Conditions: Lymphoma
Leukemia
Multiple Myeloma

Interventions: Drug: LBH589

First Posted Date: 2008-02-22

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 175

Registration Number: NCT00621244

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
MD Anderson Cancer Center/University of Texas, Houston, Texas, United States
🇩🇪
Novartis Investigative Site, Mainz, Germany

and more 1 locations

A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: Everolmus

First Posted Date: 2008-02-22

Last Posted Date: 2020-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 13

Registration Number: NCT00622258

Locations: 🇯🇵
Novartis Investigative Site, Kyoto, Japan

A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer

Phase 1

Completed

Conditions: Advanced Solid Tumors
Breast Cancer
Cowden Syndrome

Interventions: Drug: BEZ235

First Posted Date: 2008-02-21

Last Posted Date: 2020-12-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 183

Registration Number: NCT00620594

Locations: 🇺🇸
Yale University School of Medicine YaleCancerCtr-ClinTrialsOffice, New Haven, Connecticut, United States
🇺🇸
University of California at Los Angeles JonssonComprehensiveCancerCtr, Los Angeles, California, United States
🇬🇧
Novartis Investigative Site, Manchester, United Kingdom

and more 7 locations

Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Participants With Systemic Sclerosis

Phase 2

Completed

Conditions: Systemic Sclerosis, Scleroderma

Interventions: Drug: STI571

First Posted Date: 2008-02-12

Last Posted Date: 2021-07-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 27

Registration Number: NCT00613171

Locations: 🇬🇧
Novartis Investigator Site, London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy